Bringing Regenerative Medicine into the market: Allogeneic eASCs Phase IB/IIA clinical trial for treating Rheumatoid Arthritis

Project Information

REGENER-AR

Grant agreement ID: 279174

Project closed

Start date 1 January 2012

End date 31 December 2014

Funded under

• Specific Programme "Cooperation": Health

Total cost € 7 644 045,60

EU contribution € 5 925 461,50

Coordinated by

TIGENIX NV
Belgium